Lonza’s Post

View organization page for Lonza, graphic

352,373 followers

Today we reported solid financial results for the first half of 2024. With sales of CHF 3.1 billion for H1 2024, with our business performance well on track to deliver our Full-Year Outlook.   Business highlights in H1 included the signing of an agreement to acquire the Genentech large-scale mammalian facility in Vacaville (US) from Roche, which will double our global large-scale mammalian network and significantly increase our presence in the US. We welcomed Jean-Marc Huët as our new Chairman of the Board in May, and welcomed Wolfgang Wienand as our new CEO in July.   We also continued to make progress on our ESG commitments. Our emissions targets were validated by the Science Based Targets initiative (SBTi) in the First Half, and we signed a renewable energy certificate agreement that will enable our current facilities in the US to achieve 100% renewable electricity from 2026. As a result of our power agreements in Europe, the US and China, around 90% of our electricity will be renewable from 2026.   Read more about our progress in H1 2024 here: https://lnkd.in/diMHZF9m   #AHealthierWorld #AMeaningfulDifference #Growth #FinancialResults

Günter Fischer

Associate Director, EHS Lead Construction Safety, Global Engineering at LONZA

1mo

Congrats, moving forward 👍

Like
Reply
Prem Vila

Senior Associate Engineer at GlobalFoundries

5mo

Keep growing!

Like
Reply
Sixtus Usang

Head Laboratory Scientist

5mo

Impressive growth! Looking forward to a better second half.

Mike Zojaji

Expert Program Manager

5mo

Congratulations to all the talented personnel at Lonza who made this possible!

Like
Reply

congratulations to this impressive growth :).

Like
Reply
Suresh Govardhan

COO at Multi located Speciality Chemical Group.

5mo

Moving forward!

Nicholas Lorizio

Chief Executive Officer @ Astute®️ | Championing AI-Driven Growth & Cybersecurity Innovation for Digital Transformation

5mo

Amazing strides

Like
Reply
Jô L.

AI x Bioprocessing Product: A Bioconvergence Approach with Business Intelligence

5mo

Impressive growth!

Saad Qureshi

Finance Operations Manager at Lonza | MSc. | CPA Ontario Candidate

5mo

Well done!

Jenny Harte

Partner, Life Sciences KPMG: Former Biotech, Pharmaceutical, Med Tech and Devices Commercial Leader and Marketer with global, EMEA and Local market experiences. Contact Jenny.harte@kpmg.co.uk for further information.

5mo

Inspiring!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics